Drug intelligence / Profile preview

Smart-T

Development stage: Unknown
Lead developer: Self financing
Modality: Cell Therapies
Administration: Intraperitoneal

Overview

Smart-T is an introperitoneal cell therapy currently under investigation for the treatment of gastric cancer patients experiencing ascites and peritoneal metastasis. It is being evaluated in a clinical trial where it is administered in combination with an anti-PD-1 antibody. As a cell therapy, Smart-T involves the use of living cells, likely engineered immune cells, designed to specifically target and eliminate cancer cells within the peritoneal cavity. The clinical trial for Smart-T is being conducted by Self financing and The Affiliated Hospital of Nanjing University Medical School.

Beyond the preview

Go deeper on Smart-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Smart-T.

Explore the full profile